NBTXR3 First in Class Radioenhancer
Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.
Only one administration
Fits into existing standard of care:
One product addressing areas of high unmet medical needs.
See moreRecent Press Releases
NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023
Voting Rights and Shares Capital of the Company
NANOBIOTIX to Postpone Full Year 2022 Financial Results and Conference Call
ALL NANOBIOTIX PRESS RELEASES
JOIN US
“Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”
Anne-Juliette Hermant
Chief People Officer